<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251406</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-01-210</org_study_id>
    <nct_id>NCT01251406</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure</brief_title>
  <acronym>ZS-01-210</acronym>
  <official_title>A Randomized, Parallel, Placebo-controlled, Double-blind Phase IIa Study of Efficacy and Safety of Recombinant Human Neuregulin-1 (Neucardin) in Subjects With Stable Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zensun Sci. &amp; Tech. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zensun USA Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zensun Sci. &amp; Tech. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mortality of chronic heart failure patients remains high. Recombinant human Neuregulin-1
      (rhNRG-1, also called Neucardin) is a 61 amino acid peptide that acts directly on damaged
      heart muscle cells to restore their structure and function. This study will investigate the
      safety and efficacy of rhNRG-1 to treat stable chronic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess
      the safety and efficacy of rhNRG-1 also known as Neucardin as a treatment for stable chronic
      heart failure.

      A total of 120 subjects, who have chronic heart failure with a NYHA classification of II or
      III, and are on a stable regimen of ACEI/angiotensin receptor blocker (ARB), beta-blocker,
      and/or diuretic for at least 3 months prior to receiving study medication and anticipated to
      remain on the stable regimen through the treatment period can enroll as per specific
      inclusion and exclusion criteria.

      Subjects will be hospitalized for 10 days during the treatment period and will be infused
      subcutaneously with rhNRG-1 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in LVEF</measure>
    <time_frame>30 days</time_frame>
    <description>Compared to baseline and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six (6) minute walk test</measure>
    <time_frame>Day 30, 90, 180, 365</time_frame>
    <description>Compared to baseline and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire (Kansas City Cardiomyopathy Questionnaire)</measure>
    <time_frame>Day 30, 90, 180 and 365</time_frame>
    <description>Compared to baseline and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class status</measure>
    <time_frame>Day 30, 90, 180 and 365</time_frame>
    <description>Compared to baseline and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality and all cause hospitalization</measure>
    <time_frame>Days 30, 90, 180 and 365</time_frame>
    <description>Compared to baseline and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVESV and LVEDV</measure>
    <time_frame>Day 30</time_frame>
    <description>Compared to baseline and placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous administration for daily for 8 hours a day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNRG-1 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration for daily for 8 hours a day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNRG-1 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration for 8 hours a day for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily subcutaneous administration for 8 hours a day for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNRG-1 Dose 1</intervention_name>
    <description>Daily subcutaneous administration for 8 hours a day for 10 days</description>
    <arm_group_label>rhNRG-1 Dose 1</arm_group_label>
    <other_name>Neucardin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNRG-1 Dose 2</intervention_name>
    <description>Daily subcutaneous administration for 8 hours a day for 10 days</description>
    <arm_group_label>rhNRG-1 Dose 2</arm_group_label>
    <other_name>Neucardin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Male or female subjects.

          -  Have chronic heart failure defined as NYHA classification of II or III.

          -  Be on a stable regimen of ACEI/ARB and/or beta-blocker 3 months prior to receiving
             study medication and are expected to remain on a stable HF medication regime
             throughout the duration of the trial.

          -  Left ventricular ejection fraction (LVEF) of &lt; 35% as determined at screening by 2-D
             echocardiography.

          -  Is able to understand and provide informed consent.

          -  If subject has dilated cardiomyopathy, ischemic heart disease or corrected valvular
             heart disease, and had surgery to repair or replace value, the surgery must have been
             performed 3 months prior to receiving study medication and the surgical area is
             functioning normally.

          -  Proper birth control must be used at least 3 weeks prior to the study (women only),
             during the infusion period of study drug (men and women), 4-weeks after study drug
             administration (men and women) and the remaining 11 months in the study follow-up
             (women). Women must have a negative pregnancy test at screening.

          -  No greater than mild pericardial effusion &lt; 0.5 cm on echocardiography (roughly
             corresponds to &lt; 100 mL).

          -  Have an implantable cardioverter-defibrillator (ICD). The ICD should have been
             implanted at least 3 months prior to receiving study medication. Patients should
             undergo interrogation of their ICDs between 1 and 7 days before randomization to drug
             for the previous thirty (30) days. This interrogation would include surveillance for
             ventricular arrhythmias as well as assessment of ICD discharge(s) and/or
             anti-tachycardia pacing.

        Exclusion Criteria:

          -  Has chronic heart failure classified as NYHA Class I or IV.

          -  Has a history of any malignancy or positive test as specified in the pre-cancer
             screening.

          -  Have other conditions which in the opinion of the investigator preclude participation
             in the study, e.g. serious co-morbidity, known or suspected substance abuse or
             non-compliance.

          -  Has a body weight &gt;350lbs.

          -  Has had any cause hospitalization 30 days prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Greenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uri Elkayam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LAC+USC Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Clinic and Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Cardiovascular Division</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular &amp; Interventional Consultants, MD, PA</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC.</name>
      <address>
        <city>Kenner</city>
        <state>Louisiana</state>
        <zip>70065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Cardiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Center of Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cardiovascular Research Institute</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Xu Y, Li X, Liu X, Zhou M. Neuregulin-1/ErbB signaling and chronic heart failure. Adv Pharmacol. 2010;59:31-51. doi: 10.1016/S1054-3589(10)59002-1. Review.</citation>
    <PMID>20933198</PMID>
  </reference>
  <reference>
    <citation>Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, Amor R, Liu X, Li XY, Zhou MD, Graham RM, Macdonald PS. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011 Jan;13(1):83-92. doi: 10.1093/eurjhf/hfq152. Epub 2010 Sep 1.</citation>
    <PMID>20810473</PMID>
  </reference>
  <reference>
    <citation>Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, Li T, Liu X, Xu Y, Li X, Zhou M. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010 May 4;55(18):1907-14. doi: 10.1016/j.jacc.2009.12.044.</citation>
    <PMID>20430261</PMID>
  </reference>
  <reference>
    <citation>Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006 Oct 3;48(7):1438-47. Epub 2006 Sep 14.</citation>
    <PMID>17010808</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stable</keyword>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Systolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

